デフォルト表紙
市場調査レポート
商品コード
1485035

オンコロジーにおけるバイオシミラー市場- 世界の産業規模、シェア、動向、機会、予測、薬剤クラス別、がんタイプ別、流通チャネル別、地域別、競合別、2019-2029年

Oncology Biosimilars Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Drug Class, By Type of Cancer, By Distribution Channel, By Region and Competition, 2019-2029F

出版日: | 発行: TechSci Research | ページ情報: 英文 184 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.49円

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

オンコロジーにおけるバイオシミラー市場- 世界の産業規模、シェア、動向、機会、予測、薬剤クラス別、がんタイプ別、流通チャネル別、地域別、競合別、2019-2029年
出版日: 2024年05月24日
発行: TechSci Research
ページ情報: 英文 184 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

オンコロジーにおけるバイオシミラーの世界市場規模は2023年に32億7,000万米ドルとなり、予測期間では2029年までCAGR 6.84%で着実な成長が予測されています。

オンコロジーにおけるバイオシミラーの世界市場は、医薬品およびバイオテクノロジー産業の中でもダイナミックで急速に発展している分野です。様々ながんの治療に使用される生物学的製剤のバイオシミラーバージョンの開発、承認、商業化が特徴です。オンコロジーにおけるバイオシミラーは、がん治療において既に承認され広く使用されている参照生物学的製剤(オリジネーター生物学的製剤)に高度に類似するように設計された生物学的製剤です。これらのバイオシミラー医薬品は、参照生物学的製剤と同等の安全性および有効性プロファイルを維持しながら、費用対効果の高い代替品を提供するために開発されています。

市場概要
予測期間 2025-2029
市場規模:2023年 32億7,000万米ドル
市場規模:2029年 47億3,000万米ドル
CAGR:2024年-2029年 6.84%
急成長セグメント 肺がん
最大市場 北米

市場促進要因

世界のがんの有病率の上昇

コスト効率とアクセシビリティ

規制当局のサポートと承認

バイオテクノロジーの進歩

主な市場課題

特許訴訟と市場独占

医師と患者の受容

主要市場動向

オンコロジーにおけるバイオシミラー製品ポートフォリオの拡大

免疫腫瘍薬のバイオシミラー開発

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のオンコロジーにおけるバイオシミラー市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 薬剤クラス別(モノクローナル抗体、G-CSF、造血剤、その他)
    • がんタイプ別(乳がん、肺がん、胃がん、前立腺がん、子宮頸がん、血液がん、脳腫瘍、その他)
    • 流通チャネル別(小売薬局、病院薬局、オンライン薬局)
    • 地域別
    • 企業別(2023)
  • 市場マップ

第6章 北米のオンコロジーにおけるバイオシミラー市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 薬剤クラス別
    • がんタイプ別
    • 流通チャネル別
    • 国別
  • 北米:国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州のオンコロジーにおけるバイオシミラー市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 薬剤クラス別
    • がんタイプ別
    • 流通チャネル別
    • 国別
  • 欧州:国別分析
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン

第8章 アジア太平洋地域のオンコロジーにおけるバイオシミラー市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 薬剤クラス別
    • がんタイプ別
    • 流通チャネル別
    • 国別
  • アジア太平洋地域:国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第9章 南米のオンコロジーにおけるバイオシミラー市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 薬剤クラス別
    • がんタイプ別
    • 流通チャネル別
    • 国別
  • 南米:国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカのオンコロジーにおけるバイオシミラー市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 薬剤クラス別
    • がんタイプ別
    • 流通チャネル別
    • 国別
  • 中東・アフリカ:国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 最近の動向
  • 製品上市
  • 合併と買収

第13章 世界のオンコロジーにおけるバイオシミラー市場:SWOT分析

第14章 競合情勢

  • Teva Pharmaceuticals Industries Ltd.
  • STADA Arzneimittel AG
  • Shanghai Henlius Biotech, Inc.
  • Sandoz Group AG
  • Samsung Bioepis NL B.V.
  • Pfizer Inc.
  • Ligand Pharmaceuticals Inc.
  • Mylan Inc.
  • Innovent Biologics(USA), Inc.
  • Celltrion Inc.

第15章 戦略的提言

第16章 調査会社について・免責事項

目次
Product Code: 17259

Global Oncology Biosimilars Market was valued at USD 3.27 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 6.84% through 2029. The Global Oncology Biosimilars Market is a dynamic and rapidly evolving sector within the pharmaceutical and biotechnology industry. It is characterized by the development, approval, and commercialization of biosimilar versions of biologic drugs used in the treatment of various cancers. Oncology biosimilars are biologic drugs designed to be highly similar to reference biologics (originator biologic drugs) that are already approved and widely used in cancer treatment. These biosimilars are developed to provide cost-effective alternatives while maintaining comparable safety and efficacy profiles to the reference biologics.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 3.27 Billion
Market Size 2029USD 4.73 Billion
CAGR 2024-20296.84%
Fastest Growing SegmentLung Cancer
Largest MarketNorth America

Key Market Drivers

Rising Prevalence of Cancer Worldwide

The escalating prevalence of cancer worldwide is a profound and multifaceted driver that significantly influences the dynamics of the Global Oncology Biosimilars Market Cancer, often referred to as the 'modern epidemic,' has seen an alarming increase in incidence rates across the globe. This surge is attributable to a multitude of factors, including lifestyle changes, aging populations, environmental factors, and genetic predispositions. The World Health Organization (WHO) estimates that cancer will become the leading cause of death worldwide in the coming years, making it imperative to find cost-effective treatment options. Cancer's prevalence extends beyond its direct impact on healthcare systems. It infiltrates economies, imposing a substantial financial burden on individuals, families, and societies. The costs associated with cancer treatment, including biologic therapies, have been a significant concern. In this context, biosimilars, with their potential for cost savings, emerge as a promising solution.

Access to cancer treatment is not uniform across regions and socioeconomic strata. Low- and middle-income countries often face challenges in providing their populations with access to the latest cancer therapies, including biologics. The rising prevalence of cancer underscores the pressing need for accessible treatment options, and biosimilars can bridge this accessibility gap by offering effective yet more affordable alternatives. The sustainability of healthcare systems is a global concern. The relentless rise in cancer incidence strains healthcare resources, necessitating innovative solutions to maintain the quality of care. Biosimilars, by reducing the financial burden of cancer treatment, can contribute to the sustainability of healthcare systems and ensure that adequate resources are allocated to cancer care without compromising other essential medical services.

Cost-Efficiency and Accessibility

Cost-efficiency and accessibility are two interrelated drivers that exert a profound influence on the Global Oncology Biosimilars Market. The synergy between these factors not only transforms the landscape of cancer treatment but also shapes the dynamics of the biosimilars market. Cancer treatments, particularly biologic therapies, are notorious for their high costs. The economic implications of cancer treatment are a cause for concern for individuals, healthcare systems, and governments alike. As cancer prevalence rises globally, the financial burden on patients and healthcare systems escalates. This financial strain creates a compelling need for cost-effective alternatives, making biosimilars an attractive solution. Cancer can be financially devastating for patients and their families. Many cancer treatments, including biologics, are prohibitively expensive, leading to significant out-of-pocket expenses. Biosimilars, designed to offer therapeutic equivalence at a lower cost, provide relief to patients by making cancer treatment more affordable and accessible. This affordability factor enhances the quality of life for patients and ensures that they have access to vital treatments.

Cost-effective biosimilars widen the spectrum of treatment options available to healthcare providers and patients. This diversity is especially critical in oncology, where treatment plans are often tailored to the individual patient's needs. Biosimilars offer a versatile toolkit for healthcare providers, enabling them to select treatments based on both clinical effectiveness and cost-efficiency. Healthcare systems worldwide are grappling with the challenge of balancing quality care with budget constraints. The introduction of biosimilars, which are typically more affordable than their reference biologics, can lead to substantial cost savings for healthcare systems. These savings can then be reinvested in improving cancer care infrastructure, research, and other essential healthcare services.

Regulatory Support and Approval

Regulatory support and approval represent a pivotal market driver in the Global Oncology Biosimilars Market. This driver plays a central role in shaping the landscape for biosimilars and influencing their widespread adoption across the healthcare industry. Regulatory bodies worldwide have established comprehensive and stringent evaluation processes for biosimilars. These processes are designed to ensure that biosimilars are equivalent to their reference biologics in terms of quality, safety, and efficacy. The rigor of these evaluations instills confidence in healthcare providers, patients, and other stakeholders regarding the reliability and effectiveness of biosimilars. One of the most striking advantages of regulatory support is the accelerated market entry it provides for biosimilars. Compared to the protracted timelines associated with the development and approval of novel biologics, biosimilars benefit from more streamlined pathways. This expedites their availability to patients in need, addressing unmet medical needs in

Regulatory backing enhances the trust and confidence of healthcare professionals in biosimilars. Physicians and clinicians are more inclined to prescribe biosimilars when they have assurance in the regulatory processes governing these products. This trust is instrumental in fostering the adoption of biosimilars as viable treatment options. Regulatory support ensures that biosimilars maintain cost-effectiveness while upholding quality and safety standards. This is of paramount importance given the financial constraints faced by healthcare systems worldwide. Biosimilars, as cost-effective alternatives to biologics, align with the goal of achieving high-value healthcare and cost containment. The regulatory environment promotes competition in the pharmaceutical market. As biosimilars gain regulatory approval, they create competition for originator biologics. This competition exerts downward pressure on the pricing of biologics, making cancer treatment more affordable for patients and healthcare systems.

Advancements in Biotechnology

The role of advancements in biotechnology as a market driver for the Global Oncology Biosimilars Market cannot be understated. These innovations are instrumental in shaping the landscape of biosimilars and their relevance in cancer treatment Advancements in biotechnology have enabled manufacturers to create biosimilars that closely resemble their reference biologics. Through improved techniques in cell line development, protein expression, and purification, biosimilars can now achieve a higher degree of similarity in terms of structure and function. This enhanced similarity reassures healthcare professionals and patients about the efficacy and safety of biosimilars. Biotechnological progress has ushered in methods to maintain the consistency and quality of biosimilars over time. This is crucial for ensuring that biosimilars consistently deliver the same therapeutic outcomes as their reference products. Patients and healthcare providers can rely on biosimilars to provide predictable and effective treatment.

Advancements in biotechnology have broadened the scope of therapeutic indications for biosimilars. Manufacturers can now explore new therapeutic areas and expand their biosimilar portfolios. In oncology, this translates to an increasing number of treatment options for various types of cancers, catering to a wider patient population. Biotechnological innovations have led to more efficient and scalable manufacturing processes for biosimilars. This translates to increased production capacity and cost-effectiveness. As a result, biosimilars become more accessible and affordable, addressing the economic burden associated with cancer treatment.

Key Market Challenges

Patent Litigation and Market Exclusivity

Originator biologic manufacturers often resort to patent litigation to extend their market exclusivity. These legal battles can delay the entry of biosimilars into the market. The complex nature of biologics patents can lead to protracted legal disputes. Regulatory authorities may grant exclusivity extensions to reference biologics for various reasons, such as pediatric indications or orphan drug status. These extensions can further delay biosimilar market entry, limiting competition. The legal and regulatory costs associated with biosimilar development and patent litigation can be substantial. Smaller manufacturers may find it challenging to navigate these hurdles, potentially slowing down their entry into the market.

Physician and Patient Acceptance

Physicians and patients may have limited familiarity with biosimilars compared to reference biologics. This lack of awareness can lead to hesitancy in adopting biosimilars in oncology practice. Despite regulatory assurances of biosimilarity, some healthcare professionals and patients may perceive differences between biosimilars and reference biologics. This perception can create resistance to adopting biosimilars in cancer treatment. Effective education and communication about the safety and efficacy of biosimilars are essential. Not all healthcare systems invest in comprehensive educational initiatives, which can hinder adoption.

Key Market Trends

Expanding Oncology Biosimilar Portfolio

The oncology biosimilars market is witnessing an expansion of biosimilar offerings targeting a wide range of cancer types. Initially focused on breast cancer and hematologic malignancies, biosimilar manufacturers are now developing products for lung, colorectal, and gastric cancers, among others. This trend diversifies treatment options for cancer patients. Notable reference biologics in oncology, such as trastuzumab (Herceptin) and bevacizumab (Avastin), have attracted multiple biosimilar developers. This competition leads to a variety of biosimilar options for healthcare providers, promoting cost savings and enhancing access to treatment. Monoclonal antibodies represent a significant portion of oncology biologics. Biosimilar development in this category is booming, with the introduction of biosimilars for rituximab (Rituxan), cetuximab (Erbitux), and other monoclonal antibodies. These biosimilars are poised to revolutionize the treatment landscape.

Biosimilar Development for Immuno-Oncology Agents

Immuno-oncology has transformed cancer treatment paradigms. Biosimilar developers are now targeting immuno-oncology agents, including checkpoint inhibitors like pembrolizumab (Keytruda) and nivolumab (Opdivo). These biosimilars have the potential to offer cost-effective alternatives in a rapidly evolving therapeutic area. Immuno-oncology biologics are complex and costly. Biosimilars for these agents have the potential to generate substantial cost savings, making them an attractive proposition for both healthcare systems and patients. Biosimilar developers are focusing on the global market for oncology biosimilars. Expanding their reach beyond local or regional markets, manufacturers are seeking approvals in multiple countries to maximize their impact on cancer treatment worldwide.

Segmental Insights

Drug Class Insights

Based on Drug Class, Monoclonal Antibodies have emerged as the dominating segment in the global market for oncology biosimilars in 2023. Monoclonal antibodies are engineered to precisely target cancer cells or proteins implicated in cancer progression. This precise targeting minimizes adverse effects compared to conventional chemotherapy, making them attractive to both patients and healthcare providers. Numerous monoclonal antibodies have shown notable effectiveness across various cancer types by specifically binding to cancer cells and disrupting their growth or survival mechanisms, leading to enhanced patient outcomes in clinical trials. Biosimilars, which are biological products highly resembling an already approved reference biologic, exhibit no clinically significant disparities in safety, efficacy, or quality. Monoclonal antibodies are particularly suitable for biosimilar development due to their intricate structures replicable through advanced biotechnological methodologies.

Type of Cancer Insight

Based on Type of Cancer, Lung Cancer have emerged as the fastest growing segment in the Global Oncology Biosimilars Market in 2023. Lung cancer's dominance within the global oncology biosimilars market is a multifaceted phenomenon driven by several interrelated factors. The sheer prevalence of lung cancer on a global scale significantly influences the demand for effective and affordable treatment options. Lung cancer ranks among the most commonly diagnosed cancers worldwide, with its incidence steadily rising in many regions. This high prevalence necessitates a robust market for therapies, including biosimilars, which offer comparable efficacy to biologics but at potentially lower costs. The complex nature of lung cancer necessitates multimodal treatment approaches, often combining surgery, chemotherapy, radiation therapy, and targeted therapies. This complexity underscores the need for a diverse range of treatment options, including biosimilars, to address various stages and types of lung cancer comprehensively. The regulatory support and patent expirations play a crucial role in fostering biosimilar development and market penetration. Regulatory agencies worldwide have been increasingly supportive of biosimilar approval pathways, streamlining the process for manufacturers to bring these cost-effective alternatives to market. As patents for existing biologics used in lung cancer treatment expire, it creates opportunities for biosimilar manufacturers to enter the market with more affordable alternatives, driving competition and potentially lowering prices.

Regional Insights

Based on region, North America have emerged as the dominating region in the Global Oncology Biosimilars Market primarily due to several key factors. The region is home to a high incidence rate of cancer, which drives the demand for affordable treatment options like biosimilars. The presence of leading pharmaceutical companies promoting research and development of biosimilars, coupled with the robust healthcare infrastructure and favorable government policies, further contribute to the market growth. The acceptance of biosimilars as a cost-effective alternative to high-priced patented drugs has also been on a steady rise, bolstering the market's expansion in North America. The high prevalence of cancer in North America has also led to a significant demand for biosimilars in the region. With an aging population and increasing cases of chronic diseases, there is a growing need for affordable treatment options, which has further accelerated the adoption of biosimilars.

Key Market Players

Teva Pharmaceuticals Industries Ltd.

STADA Arzneimittel AG

Shanghai Henlius Biotech, Inc.

Sandoz Group AG

Samsung Bioepis NL B.V.

Pfizer Inc.

Ligand Pharmaceuticals Inc.

Mylan Inc.

Innovent Biologics (USA), Inc.

Celltrion Inc.

Report Scope:

In this report, the Global Oncology Biosimilars Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oncology Biosimilars Market, By Drug Class:

    Monoclonal Antibodies G-CSF Hematopoietic Agents Others

Oncology Biosimilars Market, By Type of Cancer:

    Breast Cancer Lung Cancer Stomach Cancer Prostate Cancer Cervical Cancer Blood Cancer Brain Cancer Others

Oncology Biosimilars Market, By Distribution Channel:

    Retail Pharmacies Hospital Pharmacies Online Pharmacies

Oncology Biosimilars Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Oncology Biosimilars Market.

Available Customizations:

Global Oncology Biosimilars Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oncology Biosimilars Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (Monoclonal Antibodies, G-CSF, Hematopoietic Agents, Others)
    • 5.2.2. By Type of Cancer (Breast Cancer, Lung Cancer, Stomach Cancer, Prostate Cancer, Cervical Cancer, Blood Cancer, Brain Cancer, Others)
    • 5.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2023)
  • 5.3. Market Map

6. North America Oncology Biosimilars Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Type of Cancer
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Oncology Biosimilars Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Type of Cancer
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Oncology Biosimilars Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Type of Cancer
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Oncology Biosimilars Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Type of Cancer
        • 6.3.3.2.3. By Distribution Channel

7. Europe Oncology Biosimilars Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Type of Cancer
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Oncology Biosimilars Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Type of Cancer
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. United Kingdom Oncology Biosimilars Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Type of Cancer
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. Italy Oncology Biosimilars Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Type of Cancer
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. France Oncology Biosimilars Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Type of Cancer
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Oncology Biosimilars Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Type of Cancer
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Oncology Biosimilars Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Type of Cancer
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Oncology Biosimilars Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Type of Cancer
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Oncology Biosimilars Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Type of Cancer
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Oncology Biosimilars Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Type of Cancer
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Oncology Biosimilars Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Type of Cancer
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Oncology Biosimilars Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Type of Cancer
        • 8.3.5.2.3. By Distribution Channel

9. South America Oncology Biosimilars Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Type of Cancer
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Oncology Biosimilars Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Type of Cancer
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Argentina Oncology Biosimilars Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Type of Cancer
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. Colombia Oncology Biosimilars Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Type of Cancer
        • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Oncology Biosimilars Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Type of Cancer
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Oncology Biosimilars Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Type of Cancer
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Saudi Arabia Oncology Biosimilars Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Type of Cancer
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. UAE Oncology Biosimilars Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Type of Cancer
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Oncology Biosimilars Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Teva Pharmaceuticals Industries Ltd.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (In case of listed)
    • 14.1.5. Recent Developments
    • 14.1.6. SWOT Analysis
  • 14.2. STADA Arzneimittel AG
  • 14.3. Shanghai Henlius Biotech, Inc.
  • 14.4. Sandoz Group AG
  • 14.5. Samsung Bioepis NL B.V.
  • 14.6. Pfizer Inc.
  • 14.7. Ligand Pharmaceuticals Inc.
  • 14.8. Mylan Inc.
  • 14.9. Innovent Biologics (USA), Inc.
  • 14.10. Celltrion Inc.

15. Strategic Recommendations

16. About Us & Disclaimer